Cat. No. 3013
Alternative Names: Melanotan I, MT-I, NDP-α-MSH
Biological ActivitySynthetic analog of α-MSH that is an agonist at melanocortin receptors (Ki values are 0.085, 0.4, 3.8 and 5.1 nM for MC1, MC3, MC4 and MC5 receptors respectively).
(Modifications: Ser-1 = N-terminal Ac, X = Nle, Phe-7 = D-Phe, Val-13 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Wikber (1999) Melanocortin receptors: perspectives for novel drugs. Eur.J.Pharmacol. 375 295. PMID: 10443584.
Sawyer et al (1980) 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultrapotent biological activity. Proc.Natl.Acad.Sci.USA 77 5754.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for [Nle4,D-Phe7]-α-MSH include:
Schellekens et al (2013) Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling. J Biol Chem 288 181. PMID: 23161547.
Do you know of a great paper that uses [Nle4,D-Phe7]-α-MSH from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: [Nle4,D-phe7]-alpha-MSH, supplier, Melanocortin, receptor, agonists, MC, Receptors, [Nle4, D-phe7]-α-MSH, alpha-MSH, MelanotanI, Tocris Bioscience, Melanocortin (MC) Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonist
April 22 - 26, 2017
Chicago, IL, USA